All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ChAdOx1 nCoV-19
Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca PLC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 05, 2021
Details:
The manufacture of the COVID-19 vaccine, AZD1222, will be undertaken by Daiichi Sankyo Biotech Company, at a facility dedicated to the Ministry of Health, Labour and Welfare’s “project to establish a system for developing and producing novel influenza virus vaccines.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Isavuconazonium Sulfate
Therapeutic Area: Infections and Infectious Diseases Product Name: Cresemba
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2021
Details:
The phase 3 study enrolled 103 patients and is assessing the safety and efficacy of isavuconazole in adult Japanese patients suffering from deep-seated mycoses, including invasive aspergillosis and mucormycosis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Avigan
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2020
Details:
The Japanese Health Ministry said on Monday its medical review board concluded that clinical trial data to determine the efficacy of Fujifilm Holdings Corp’s COVID-19 drug candidate Avigan is inconclusive.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dexamethasone
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 22, 2020
Details:
The full results of the large randomised clinical trial released in the New England Journal of Medicine confirmed the benefits for people with advanced or moderate disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Delamanid
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 25, 2020
Details:
Deltyba has potent bactericidal activity against Mycobacterium tuberculosis and is the first approved compound from the bicyclic nitro-imidazole derivatives for the treatment of pulmonary MDR-TB in adult patients.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Influenza HA Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Vaccine
Partner/Sponsor/Collaborator: Kitasato Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $3.5 million
Deal Type: Agreement March 27, 2020
Details:
After a review of sales strategy and discussions, the companies have reached an agreement to terminate the cooperative sales agreement for Influenza HA Vaccine.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
